Ocugen
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2013-01-01
- Employees
- 65
- Market Cap
- $382.8M
- Website
- http://www.ocugen.com
- Introduction
Ocugen, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies to cure eye diseases. Its product pipeline candidates include OCU400, OCU410, OCU200, and COVAXIN. The firm's modifier gene therapy platform is engaged in addressing retinal diseases, including retinitis pigmentosa, leber congenital amaurosis, and...
Expanded Access Program for RP in Adults
- Conditions
- First Posted Date
- 2024-08-28
- Last Posted Date
- 2024-11-22
- Lead Sponsor
- Ocugen
- Registration Number
- NCT06574997
- Locations
- 🇺🇸
Associated Retina Consultants, Phoenix, Arizona, United States
🇺🇸Advanced Research, Deerfield Beach, Florida, United States
A Phase 3 Study Of OCU400 Gene Therapy for the Treatment Of Retinitis Pigmentosa
- Conditions
- Interventions
- First Posted Date
- 2024-04-29
- Last Posted Date
- 2024-09-30
- Lead Sponsor
- Ocugen
- Target Recruit Count
- 150
- Registration Number
- NCT06388200
- Locations
- 🇺🇸
Advanced Research, LLC., Deerfield Beach, Florida, United States
🇺🇸Bascom Palmer Eye Institute, University of Miami, Miller School of Medicine, Miami, Florida, United States
🇺🇸Retina Foundation of the Southwest, Dallas, Texas, United States
Study to Assess the Safety and Efficacy of OCU410 for Geographic Atrophy
- First Posted Date
- 2023-08-30
- Last Posted Date
- 2024-09-30
- Lead Sponsor
- Ocugen
- Target Recruit Count
- 63
- Registration Number
- NCT06018558
- Locations
- 🇺🇸
Miidwest Eye Institute, Carmel, Indiana, United States
🇺🇸Mid Atlantic Retina, Cherry Hill, New Jersey, United States
🇺🇸The University of Pittsburgh, Pittsburgh, Pennsylvania, United States
Study to Assess the Safety and Efficacy of OCU410ST for Stargardt Disease
- First Posted Date
- 2023-07-21
- Last Posted Date
- 2024-03-12
- Lead Sponsor
- Ocugen
- Target Recruit Count
- 42
- Registration Number
- NCT05956626
- Locations
- 🇺🇸
Mississippi Retina Associates, Jackson, Mississippi, United States
🇺🇸Retina Foundation of the Southwest, Dallas, Texas, United States
🇺🇸Bascom Palmer Eye Institute, Miami, Florida, United States
Phase I Study to Assess the Safety and Efficacy of OCU200 for Center-Involved Diabetic Macular Edema (DME)
- Conditions
- Interventions
- First Posted Date
- 2023-04-06
- Last Posted Date
- 2023-04-06
- Lead Sponsor
- Ocugen
- Target Recruit Count
- 28
- Registration Number
- NCT05802329
Expanded Access Program of Whole, Inactivated COVID-19 Vaccine COVAXIN™ (BBV152) in Adults Aged 18 Years and Older
- Conditions
- First Posted Date
- 2022-09-15
- Last Posted Date
- 2022-09-22
- Lead Sponsor
- Ocugen
- Registration Number
- NCT05541289
- Locations
- 🇺🇸
Woods, Langhorne, Pennsylvania, United States
Immuno-bridging and Broadening Study of a Whole, Inactivated COVID-19 Vaccine BBV152 in Healthy Adults
- First Posted Date
- 2022-02-28
- Last Posted Date
- 2023-03-27
- Lead Sponsor
- Ocugen
- Target Recruit Count
- 400
- Registration Number
- NCT05258669
- Locations
- 🇺🇸
Voyage Medical, Tempe, Arizona, United States
🇺🇸Clinical Site Partners, Winter Park, Florida, United States
🇺🇸Palm Springs Community Health Center, Miami Lakes, Florida, United States
Study to Assess the Safety and Efficacy of OCU400 for Retinitis Pigmentosa and Leber Congenital Amaurosis
- Conditions
- Interventions
- First Posted Date
- 2022-01-24
- Last Posted Date
- 2023-10-25
- Lead Sponsor
- Ocugen
- Target Recruit Count
- 124
- Registration Number
- NCT05203939
- Locations
- 🇺🇸
Associated Retina Consultants, Phoenix, Arizona, United States
🇺🇸Ocugen Site 5 - University of California, San Diego (UCSD) - Shiley Eye Institute, La Jolla, California, United States
🇺🇸Ocugen Site 3 - Bascom Palmer Eye Institute, Miami, Florida, United States
Study of Brimonidine Tartrate Nanoemulsion Eye Drop Solution in the Treatment of Dry Eye Disease (DED)
- First Posted Date
- 2018-12-24
- Last Posted Date
- 2022-07-18
- Lead Sponsor
- Ocugen
- Target Recruit Count
- 252
- Registration Number
- NCT03785340
- Locations
- 🇺🇸
Ophthalmology Associates, Saint Louis, Missouri, United States
🇺🇸Martel Medical Eye Group, Rancho Cordova, California, United States
🇺🇸Rand Eye Institute, Pompano Beach, Florida, United States
Study of Brimonidine Tartrate Nanoemulsion Eye Drops in Patients With Ocular Graft-vs-Host Disease
- First Posted Date
- 2018-07-19
- Last Posted Date
- 2022-07-06
- Lead Sponsor
- Ocugen
- Target Recruit Count
- 59
- Registration Number
- NCT03591874
- Locations
- 🇺🇸
Emory Eye Center, Atlanta, Georgia, United States
🇺🇸Ohio State University, Columbus, Ohio, United States
🇺🇸University of Penn Scheie Eye Institute,, Philadelphia, Pennsylvania, United States